19KA Stock Chart & Stats
€6.93
-€0.26(-3.85%)
At close: 4:00 PM EDT
€6.93
-€0.26(-3.85%)
Day’s Range― - ―
52-Week Range€5.20 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€506.28M
Enterprise Value€613.76M
Total Cash (Recent Filing)€256.69M
Total Debt (Recent Filing)€145.15M
Price to Earnings (P/E)3.0
Beta1.03
Next Earnings
Nov 11, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding77,944,320
10 Day Avg. Volume25
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.57Price Target Upside81.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.43
Revenue Forecast (FY)€296.35M
Bulls Say, Bears Say
Bulls Say
Broad Dialysis-provider AccessCoverage across all five leading dialysis providers gives DefenCath broad access to its target market and can support protocol adoption, recurring demand, and more efficient commercial scaling as pilots expand.
Strong Profitability And Cash GenerationHigh margins and free cash flow nearly matching net income indicate strong earnings quality and financial flexibility. This provides resources to fund commercialization, pipeline development, and balance-sheet needs without relying heavily on external capital.
Protected Antibiotic FranchiseThe upheld patents protect MINOCIN from early generic competition, supporting revenue visibility and preserving the commercial value of the acquired antibiotic franchise while CorMedix expands its broader product portfolio.
Bears Say
Reimbursement Transition RiskDefenCath adoption and revenue depend partly on reimbursement economics. Changes after TDAPA, uncertain Medicare Advantage contracting, and the pending ESRD rule could pressure ordering behavior, pricing, or provider participation.
Limited Earnings HistoryThe recent profitability and cash-generation profile is a sharp departure from prior losses and weak revenue. This limited track record makes long-term earnings durability less certain if product adoption, reimbursement, or execution weakens.
Higher Structural Operating CostsThe acquired business and planned commercial expansion have materially increased the operating-cost base. Sustaining strong margins will require continued revenue growth and successful integration, particularly as hiring increases for potential REZZAYO commercialization.
Cormedix News
19KA FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was €5.20 and its highest was €11.80 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is €506.28M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 11, 2026 which is in 34 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 13, 2026. The company reported €0.259 earnings per share for the quarter, beating the consensus estimate of €0.212 by €0.046.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is -0.09.
How many shares outstanding does Cormedix have?
Cormedix has 77,944,320 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of €0.259 in its last earnings report, beating expectations of €0.212. Following the earnings report the stock price went down -1.883%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in DE:19KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.57 (81.40% Upside)
€12.57 (81.40% Upside)
Blogger Sentiment
Bullish
DE:19KA Sentiment 78%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
44.64%
Trailing 12-Months
Asset Growth
257.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
19KA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably large revenue and adjusted EBITDA growth), solid cash generation, strategic commercial agreements with all top 5 dialysis providers, and meaningful pipeline progress highlighted by positive Phase III data for REZZAYO and an anticipated sNDA submission. These positives were tempered by higher operating expenses (driven by the Melinta acquisition and planned commercial investments), uncertainty around post-TDAPA ordering patterns and final ESRD reimbursement, and the limited current visibility on the impact of the new LDO pilot and Medicare Advantage contracting. On balance, the magnitude of the operational and financial wins (large YoY revenue and EBITDA growth, strong cash flow, clear regulatory/pipeline momentum) outweighs the near-term expense increases and reimbursement uncertainties.View all DE:19KA earnings summaries19KA Stock 12 Month Forecast
Average Price Target
€12.57
▲(81.40% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―